

# GSK Completes Acquisition of Gunderson Dettmer Client Affinivax

Client News

August 16, 2022

Gunderson Dettmer represented biopharmaceutical company Affinivax, Inc. in its completed acquisition by global healthcare company GSK for \$3.3 billion. **The initial announcement** between the two companies occurred on May 31, 2022, when it was announced that GSK will pay \$2.1 billion upfront and up to \$1.2 billion in potential development milestones. To continue GSK's strategy of building a strong portfolio of specialty medicines and vaccines, GSK will leverage Affinivax's technology platform Multiple Antigen Presenting System (MAPS) to develop advanced next-generation vaccines, including the 24-valent pneumococcal vaccine candidate. Gunderson has represented Affinivax, Inc. since incorporation.

In the **announcement of the completed acquisition**, Chief Scientific Officer of GSK Tony Wood said, "Affinivax's exciting pneumococcal vaccine candidates, the potentially disruptive MAPs technology and their fantastic scientific talent, further strengthen our pipeline of novel vaccines and presence in the Boston area."

The Gunderson Dettmer deal team was led by Tim Ehrlich and included corporate associates Graham Rogers, Gabriella Stearns and Sandra Lucero, M&A partner Andrew Luh and associates Matt Martinez and Alice Billmire, public companies partner Keith Scherer and associate John Maciejewski, tax/ fund partner Mark Foster and associate Morgan Otway, executive compensation partner Jim Hauser and associate Chris Shin, labor and employment partner Natalie Pierce and associate Jeff Salomon, and tech/IP associates Beatrice Igne-Bianchi, Julie Bateman, Rithika Kulathila, Keon L. Seif-Naraghi, Lydia Carnvale, and Shagun Parekh.

## Companies:

Affinivax

GSK

## Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Graham G. Rogers

ASSOCIATE

P +1 617 648 9332

Sandra Lucero

ASSOCIATE

P +1 617 648 9221

Andrew Luh

PARTNER

P +1 650 463 5312

Matthew G. Martinez

COUNSEL

P +1 415 801 4865

Keith J. Scherer

PARTNER

P +1 617 648 9231

John E. Maciejewski

ASSOCIATE

P +1 617 648 9242

Mark M. Foster

PARTNER

P +1 650 463 5343

Morgan L. Otway

ASSOCIATE

P +1 212 430 4206

Jim Hauser

PARTNER

P +1 617 648 9146

Natalie A. Pierce

PARTNER

P +1 415 801 4920

Jeff I. Salomon

OF COUNSEL

P +1 646 797 5514

## Related Services

Employment & Labor

Executive Compensation

Late-Stage Company

Life Sciences Licensing & Strategic Partnering

Mergers & Acquisitions

Tax

## Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)